383 related articles for article (PubMed ID: 16316401)
1. CD4(+) T-cell responses against the VP1-unique region in individuals with recent and persistent parvovirus B19 infection.
Lindner J; Barabas S; Saar K; Altmann D; Pfister A; Fleck M; Deml L; Modrow S
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):356-61. PubMed ID: 16316401
[TBL] [Abstract][Full Text] [Related]
2. T-helper cell-mediated interferon-gamma, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19.
Franssila R; Hedman K
Vaccine; 2004 Sep; 22(27-28):3809-15. PubMed ID: 15315862
[TBL] [Abstract][Full Text] [Related]
3. Persistent parvovirus B19 infection detected by specific CD4+ T-cell responses in a patient with hepatitis and polyarthritis.
Pongratz G; Lindner J; Modrow S; Schimanski S; Schölmerich J; Fleck M
J Intern Med; 2009 Sep; 266(3):296-301. PubMed ID: 19549095
[TBL] [Abstract][Full Text] [Related]
4. B cell memory is directed toward conformational epitopes of parvovirus B19 capsid proteins and the unique region of VP1.
Corcoran A; Mahon BP; Doyle S
J Infect Dis; 2004 May; 189(10):1873-80. PubMed ID: 15122524
[TBL] [Abstract][Full Text] [Related]
5. Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis.
Azzi A; Manaresi E; Zakrzewska K; DeSantis R; Musiani M; Zerbini M
J Med Virol; 2004 Apr; 72(4):679-82. PubMed ID: 14981773
[TBL] [Abstract][Full Text] [Related]
6. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection.
Von Landenberg P; Lehmann HW; Knöll A; Dorsch S; Modrow S
Arthritis Rheum; 2003 Jul; 48(7):1939-47. PubMed ID: 12847688
[TBL] [Abstract][Full Text] [Related]
7. IgE, CD8(+)CD60+ T cells and IFN-alpha in human immunity to parvovirus B19 in selective IgA deficiency.
Bluth MH; Norowitz KB; Chice S; Shah VN; Nowakowski M; Durkin HG; Smith-Norowitz TA
Hum Immunol; 2005 Oct; 66(10):1029-38. PubMed ID: 16386644
[TBL] [Abstract][Full Text] [Related]
8. Antibody-mediated opsonization of red blood cells in parvovirus B19 infection.
Chehadeh W; Halim MA; Al-Nakib W
Virology; 2009 Jul; 390(1):56-63. PubMed ID: 19450862
[TBL] [Abstract][Full Text] [Related]
9. Parvovirus B19 viral loads in relation to VP1 and VP2 antibody responses in diagnostic blood samples.
Beersma MF; Claas EC; Sopaheluakan T; Kroes AC
J Clin Virol; 2005 Sep; 34(1):71-5. PubMed ID: 15985386
[TBL] [Abstract][Full Text] [Related]
10. Reconstituted immunity against persistent parvovirus B19 infection in a patient with acquired immunodeficiency syndrome after highly active antiretroviral therapy.
Chen MY; Hung CC; Fang CT; Hsieh SM
Clin Infect Dis; 2001 May; 32(9):1361-5. PubMed ID: 11303273
[TBL] [Abstract][Full Text] [Related]
11. Human parvovirus B19 serology and avidity using a combination of recombinant antigens enables a differentiated picture of the current state of infection.
Pfrepper KI; Enders M; Motz M
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):362-5. PubMed ID: 16316402
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo cytokine responses against parvovirus B19 antigens in previously infected pregnant women.
Corcoran A; Mahon BP; McParland P; Davoren A; Doyle S
J Med Virol; 2003 Jul; 70(3):475-80. PubMed ID: 12767014
[TBL] [Abstract][Full Text] [Related]
13. The association of VP1 unique region protein in acute parvovirus B19 infection and anti-phospholipid antibody production.
Tzang BS; Tsay GJ; Lee YJ; Li C; Sun YS; Hsu TC
Clin Chim Acta; 2007 Mar; 378(1-2):59-65. PubMed ID: 17169353
[TBL] [Abstract][Full Text] [Related]
14. Evidence for persistence of human parvovirus B19 DNA in bone marrow.
Cassinotti P; Burtonboy G; Fopp M; Siegl G
J Med Virol; 1997 Nov; 53(3):229-32. PubMed ID: 9365887
[TBL] [Abstract][Full Text] [Related]
15. Adaptive immune responses against parvovirus B19 in patients with myocardial disease.
Lindner J; Noutsias M; Lassner D; Wenzel J; Schultheiss HP; Kuehl U; Modrow S
J Clin Virol; 2009 Jan; 44(1):27-32. PubMed ID: 18980860
[TBL] [Abstract][Full Text] [Related]
16. Human parvovirus B19 infection during pregnancy--value of modern molecular and serological diagnostics.
Enders M; Schalasta G; Baisch C; Weidner A; Pukkila L; Kaikkonen L; Lankinen H; Hedman L; Söderlund-Venermo M; Hedman K
J Clin Virol; 2006 Apr; 35(4):400-6. PubMed ID: 16332455
[TBL] [Abstract][Full Text] [Related]
17. Tracking of peptide-specific CD4+ T-cell responses after an acute resolving viral infection: a study of parvovirus B19.
Kasprowicz V; Isa A; Tolfvenstam T; Jeffery K; Bowness P; Klenerman P
J Virol; 2006 Nov; 80(22):11209-17. PubMed ID: 16943301
[TBL] [Abstract][Full Text] [Related]
18. T helper cell-mediated in vitro responses of recently and remotely infected subjects to a candidate recombinant vaccine for human parvovirus b19.
Franssila R; Hokynar K; Hedman K
J Infect Dis; 2001 Mar; 183(5):805-9. PubMed ID: 11181158
[TBL] [Abstract][Full Text] [Related]
19. Follow-up study of clinical and immunological findings in patients presenting with acute parvovirus B19 infection.
Kerr JR; Coyle PV; DeLeys RJ; Patterson CC
J Med Virol; 1996 Jan; 48(1):68-75. PubMed ID: 8825713
[TBL] [Abstract][Full Text] [Related]
20. Frequent infection with a viral pathogen, parvovirus B19, in rheumatic diseases of childhood.
Lehmann HW; Knöll A; Küster RM; Modrow S
Arthritis Rheum; 2003 Jun; 48(6):1631-8. PubMed ID: 12794831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
